In this study we randomly compared the estradiol Outing stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent. (c) 2005 Elsevier Inc. All rights reserved.
17-beta-estradiol eluting stent versus phosphorylcholine-coated Stent for the treatment of native coronary artery disease / Flavio, Airoldi; Carlo Di, Mario; Flavio, Ribichini; Patrizia, Presbitero; Paolo, Sganzerla; Valeria, Ferrero; Corrado, Vassanelli; Carlo, Briguori; Mauro, Carlino; Matteo, Montorfano; BIONDI ZOCCAI, Giuseppe; Alaide, Chieffo; Angela, Ferrari; Antonio, Colombo. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - STAMPA. - 96:5(2005), pp. 664-667. [10.1016/j.amjcard.2005.04.040]
17-beta-estradiol eluting stent versus phosphorylcholine-coated Stent for the treatment of native coronary artery disease
BIONDI ZOCCAI, GIUSEPPE;
2005
Abstract
In this study we randomly compared the estradiol Outing stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent. (c) 2005 Elsevier Inc. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
